Dr. Reddy’s Laboratories informs about press release

05 Jun 2023 Evaluate

Dr. Reddy’s Laboratories has informed that it enclosed a press release titled ‘Dr. Reddy’s successfully completes Phase I study (IV route) of DRL_TC, a proposed biosimilar of tocilizumabp’.

The above information is a part of company’s filings submitted to BSE.

Dr. Reddys Lab Share Price

1318.00 18.60 (1.43%)
25-Feb-2026 12:39 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1763.40
Dr. Reddys Lab 1318.00
Cipla 1340.00
Zydus Lifesciences 915.55
Lupin 2292.00
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×